BioMarin Pharmaceuticals (BMRN)

BioMarin Pharmaceuticals (BMRN) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.

BioMarin Extends Gains as Investors Weigh Growth Prospects

BioMarin rose 3.8% today, outpacing the S&P 500’s 0.8% gain and the Nasdaq 100’s 1.8% rise. The move extends a strong recent run as investors assess growth from acquired rare-disease drugs and the company’s pipeline.

Published 2026-11-19 15:00:42 UTC.